Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany
Article in Cost Effectiveness and Resource Allocation (March 2024)
The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.
Cost-utility analysis of eribulin versus capecitabine in HER-2 negative advanced or metastatic breast cancer in China
Preprint in Research Square (December 2022)
An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry
Article in Acta Oncologica (June 2020)